— Revenue of $1.347 Billion Increases 55.6%, 54.2% in Constant Currency —
— Organic Revenue Increases 72.5%, 70.9% in Constant Currency, as Strong Sales of COVID Tests Offset Declines in Other Businesses —
— Company Posts GAAP Diluted EPS of $1.88, Non-GAAP Diluted EPS of $2.07 —
MARLBOROUGH, Mass.–(BUSINESS WIRE)–#earnings–Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 26, 2020.
“We capped off an unprecedented fiscal year with remarkable financial results in our fourth quarter,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “These results were driven by the tireless efforts of our Diagnostics, European and supply chain teams to provide COVID-19 tests, and by steady improvement in our other businesses compared to the June quarter.”
- Revenue increased 55.6% for the quarter, or 54.2% in constant currency, including revenue from the divested Medical Aesthetics business in the prior year period. Excluding material acquisitions and divestitures, organic revenue in the fourth quarter increased 72.5%, or 70.9% in constant currency.
- Worldwide Molecular Diagnostics revenue of $818.9 million increased 375.8%, or 370.8% in constant currency, far exceeding expectations based on increased production of, and strong global demand for, the Company’s two SARS-CoV-2 assays that run on the fully automated Panther® and Panther Fusion® systems.
- GAAP earnings per share (EPS) were $1.88, compared to ($0.46) in the prior year period. Non-GAAP EPS of $2.07 increased 218.5% over the prior year period.
- Completed the acquisition of Acessa Health, strengthening the Company’s leadership position in the GYN surgical space, for approximately $80 million in cash plus contingent payments based on future revenue growth.
- Completed a $950 million private placement of 3.250% senior unsecured notes due 2029. Used the proceeds of the offering and available cash to refinance the 4.375% senior unsecured notes due 2025, which were called and retired on October 15.
- Cash flow from operations was $442.0 million in the fourth quarter. Based on this strong cash flow, the Company repaid $250 million of debt under its revolving credit facility, and repurchased 1.7 million shares of its common stock for $100.2 million.
Key financial results for the fiscal fourth quarter are shown in the table below.
- Ad -
- Ad -
Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. GAAP financial results for the fourth quarter of fiscal 2019 reflect the Company’s 2019 10-K filing, which included additional impairment charges related to the Medical Aesthetics divestiture that were finalized after the Company issued its fourth quarter earnings release on November 6, 2019. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Organic revenue is on a constant currency basis and excludes the divested Blood Screening and Medical Aesthetics businesses, as well as the acquired SSI and Acessa businesses.
$ in millions
Cytology & Perinatal
Interventional Breast Solutions
Total Breast Health
Excluding divested Blood and
Excluding divestitures and SSI,
Acessa acquisitions (organic)
* Hologic completed the divestiture of its Medical Aesthetics business on December 30, 2019.
Other Financial Highlights
- U.S. revenue of $994.9 million increased 51.6%. International revenue of $352.1 million increased 68.0%, or 62.1% in constant currency. Organically, U.S. revenue of $985.0 million increased 64.0%, while international revenue of $346.8 million increased 102.2%, or 95.0% in constant currency.
- GAAP gross margin of 69.2% increased 4,040 basis points, primarily due to sales of SARS-CoV-2 tests and non-cash impairment charges in the prior year period associated with the Medical Aesthetics divestiture. Non-GAAP gross margin of 74.2% increased 1,250 basis points, primarily due to sales of SARS-CoV-2 tests and the divestiture of the lower margin Medical Aesthetics business.
- GAAP operating margin was 47.0%, compared to an operating loss of (10.0%) in the prior year period. Non-GAAP operating margin of 53.7% increased 2,430 basis points, primarily due to sales of SARS-CoV-2 tests and the divestiture of the lower margin Medical Aesthetics business.
- GAAP net income attributable to Hologic was $495.0 million, compared to a net loss of ($123.5) million in the prior year period. Non-GAAP net income attributable to Hologic of $543.7 million increased 210.7%. Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $748.5 million, an increase of 169.5%.
- Total principal debt outstanding at the end of the fourth quarter was $3.1 billion. The Company ended the quarter with cash and equivalents of $701.0 million, and a net leverage ratio (net debt over adjusted EBITDA) of 1.5 times.
- On a trailing 12 months basis, adjusted Return on Invested Capital (ROIC) of 18.5% increased 550 basis points compared to the prior year period.
Financial Guidance for the First Quarter of Fiscal 2021
“We expect our strong financial performance to continue in the first quarter of fiscal 2021, driven by our COVID tests and continued recovery of our other businesses,” said Karleen Oberton, Hologic’s Chief Financial Officer.
Hologic’s financial guidance for the first quarter of fiscal 2021 is shown in the table below. The guidance is based on a non-GAAP tax rate of approximately 22.75%, and diluted shares outstanding of approximately 263 million for the quarter. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2021 as in fiscal 2020. Current guidance assumes that recent foreign exchange rates persist for all of the first quarter of fiscal 2021. Organic revenue guidance is on a constant currency basis and excludes the divested Blood Screening and Medical Aesthetics businesses, as well as the acquired Acessa business.
Guidance for the First Quarter of Fiscal 2021
$1,350 – $1,425
58.7% to 67.6%
56.6% – 65.4%
71.1% – 80.8%
$1.88 – $2.03
31.5% – 42.0%
$2.10 – $2.25
244.3% – 268.9%
Use of Non-GAAP Financial Measures
The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) additional depreciation expense from acquired fixed assets and accelerated depreciation related to consolidation and closure of facilities; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value and adjustments to contingent consideration; (iv) restructuring and divestiture charges and facility closure and consolidation charges and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to its divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of forward foreign currency contracts and foreign currency option contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impact of tax reform and other one-time impacts related to internal restructuring and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company’s core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines organic revenue to exclude the divested Blood Screening and Cynosure businesses, and the acquired SSI and Acessa businesses.
These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The company’s definition of these non-GAAP measures may differ from similarly titled measures used by others.
The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Hologic’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic’s business.
Because non-GAAP financial measures exclude the effect of items that will increase or decrease the company’s reported results of operations, management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
Conference Call and Webcast
Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the fourth quarter of fiscal 2020. Approximately 10 minutes before the call, dial 888-204-4368 (in the U.S. and Canada) or +1 323-994-2093 (international) and enter access code 9969459. A replay will be available approximately two hours after the call ends through Friday, November 27, 2020. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 9969459, PIN 7018. The Company will also provide a live webcast of the call at investors.hologic.com.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company’s outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, trade relations, and related uncertainties; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.
The risks included above are not exhaustive. Other factors that could adversely affect the Company’s business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE: Hologic, Inc.
Three Months Ended
Service and other
Cost of revenues:
Amortization of intangible assets
Impairment of intangible assets and equipment
Service and other
Research and development
Selling and marketing
General and administrative
Amortization of intangible assets
Impairment of intangible assets and equipment
Restructuring and divestiture charges
Total operating expenses
Income (loss) from operations
Debt extinguishment loss
Other income (expense), net
Income (loss) before income taxes
Provision (benefit) for income taxes
Net income (loss)
Net loss attributable to noncontrolling interest
Net income (loss) attributable to Hologic
Net income (loss) per common share attributable to Hologic:
Weighted average number of shares outstanding:
Cash and cash equivalents
Accounts receivable, net
Other current assets
Total current assets
Property, plant and equipment, net
Goodwill and intangible assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt
Accounts payable and accrued liabilities
Total current liabilities
Long-term debt, net of current portion
Deferred income taxes
Other long-term liabilities
Total Hologic stockholders’ equity
Total liabilities and stockholders’ equity
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation expense
Deferred income taxes
Intangible asset and equipment impairment charges
Other adjustments and non-cash items
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
Prepaid income taxes
Prepaid expenses and other assets
Accrued expenses and other liabilities
Net cash provided by operating activities
Acquisition of businesses, net of cash acquired
Net proceeds from sale of business
Purchase of equity method investment in SSI
Loans to SSI
Purchase of property and equipment
Increase in equipment under customer usage agreements
Purchase of cost-method investment
Purchase of insurance contracts
Purchase of intellectual property
Net cash used in investing activities
Proceeds from long-term debt
Repayment of long-term debt
Proceeds from revolving credit line
Repayments under revolving credit line
Proceeds from accounts receivable securitization program
Repayments under accounts receivable securitization program
Purchase of non-controlling interest
Repurchases of common stock
Payment of debt issuance costs
Payoff of acquired long term debt
Payment of deferred acquisition consideration
Purchase of interest rate caps
Net proceeds from issuance of common stock under employee stock plans
Payment of minimum tax withholdings on net share settlements of equity awards
Payments under finance lease obligations
Net cash used in financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Vice President, Investor Relations and Corporate Communications